Effect of sodium-glucose co-transporter 2 inhibitors on plasma potassium: A meta-analysis
Pooled result · Hyperkalaemia eventsResult — go to the resultPooled odds ratio 0.72 95% CI 0.61–0.85Authors' conclusion
Use of SGLT2 inhibitors in T2DM reduced odds of inducing hyperkalaemia but had a minimal effect of lowering serum potassium.
Study context
- Population
- RCTs of SGLT2i in T2DM reporting potassium or hyperkalaemia as primary or secondary outcomes (MEDLINE and PubMed to 31st December 2020)9 RCTs
- Comparison
- SGLT2i vs placebo
- Outcome
- Hyperkalaemia events
Methodological detailsfixed-effects (hyperkalaemia events), random-effects (potassium MD), 1724 publications identified; 3 reported hyperkalaemia events, 5 serum potassium, 1 both
- Fixed-effects (hyperkalaemia events)
- Random-effects (potassium MD)
- 1724 publications identified; 3 reported hyperkalaemia events, 5 serum potassium, 1 both
Pooled result
As reported in the abstract
Pooled odds ratio
0.72
95% CI 0.61–0.85
P < 0.001
SGLT2 inhibitorvs Placebo
pooled OR 0.72 (95% CI 0.61–0.85); P < 0.001
Further pooled results
| Outcome | Pooled MD (mmol/L) (95% CI) | P value | |
|---|---|---|---|
| Serum potassium concentrationI2 of 89% · random-effects | −0.04 (−0.08 to 0.00) | P = 0.04 | |
| −0.1−0.0500.05Difference, mmol/L (linear scale) |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Effect of sodium-glucose co-transporter 2 inhibitors on plasma potassium: A meta-analysis. Diabetes Res Clin Pract. Published 5 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →